Date: 2014-09-09
Type of information: Grant
Company: F2G (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £1.4 million
Funding type: grant
Planned used: The grant will be used to accelerate the development of F2G’s novel IV/oral systemic antifungal F901318. The project will focus on the oral Phase I clinical development of F901318 and supporting studies, and will allow the company to accelerate its clinical development activities. F901318 is being developed as an IV and oral therapy to treat invasive aspergillosis and other life-threatening fungal infections. The product belongs to a new class of antifungal acting against a new cellular target. F901318 is highly active against all known azole-resistant aspergilli.
Others: * On September 9, 2014, F2G, a UK-based antifungal drug discovery and development company, announced a major funding award of £1.4 million from the Technology Strategy Board’s Biomedical Catalyst. The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy.
Therapeutic area: Infectious diseases
